Welcome to our dedicated page for Atlas Energy news (Ticker: CANSF), a resource for investors and traders seeking the latest updates and insights on Atlas Energy stock.
Atlas Energy Corp. (CANSF) generates news that reflects its role as an international upstream oil and gas royalty and streaming company and its evolution from Willow Biosciences Inc. Company announcements have described a significant recapitalisation, the completion of a TSX Venture Exchange listing under the symbol ATLE, and changes to its trading status on U.S. over-the-counter markets.
Earlier news releases issued under Willow Biosciences Inc. provide important background for investors tracking this symbol. Those disclosures cover the sale of Willow’s wholly owned operating subsidiary, the resulting status of Willow as having no active business, and the subsequent reorganization and investment agreement that provided for a private placement, new executive leadership, a reconstituted board of directors, and a name change to Atlas Energy Corp. They also outline the expected transition of the listing from the Toronto Stock Exchange to the TSX Venture Exchange and the use of the TSXV Sandbox program.
More recent communications under the Atlas Energy name highlight the company’s upstream royalty and streaming focus, the initial recapitalisation, and its status as a TSXV Sandbox issuer. News items also describe the voluntary delisting of the company’s common shares from the OTCQB and continued trading on the TSX Venture Exchange and OTC Pink market.
Investors following CANSF-related news can review this history to understand how the business focus shifted from precision fermented ingredients and biomanufacturing under Willow Biosciences to oil and gas royalty and streaming interests under Atlas Energy Corp., as well as how the company’s capital structure and listing venues have changed over time.
Willow Biosciences Inc. (OTCQB: CANSF) has announced a commercial agreement with Sandhill One, LLC, following successful development of their BioOxi™ bio-oxidation platform for ursodeoxycholic acid (UDCA). This bioactive compound is essential in treating cholestatic liver disease and gallstone conditions. The innovative collaboration aims to provide a more sustainable, cost-effective production method for UDCA, eliminating reliance on animal-sourced materials. Willow anticipates receiving a significant percentage of Sandhill’s end-market revenues, enhancing potential royalty income. The agreement underscores Willow's commitment to expanding company growth and achieving targeted milestones for 2023.
Willow Biosciences Inc. (OTCQB: CANSF) has launched its new BioOxi™ platform, enhancing its strain engineering and precision fermentation capabilities. This technology streamlines the production of oxygenated and hydroxylated functional ingredients by eliminating several chemical steps, which significantly lowers production costs and resources. The platform aims to expand revenue opportunities by providing faster product innovation for commercial partners. Willow's recent collaborations show the potential for BioOxi to support new business developments and generate additional licensing or royalty revenues. The company believes this strategic move will broaden its market and accelerate revenue generation in the rapidly evolving biotech sector.
Willow Biosciences Inc. (CANSF) announced key management promotions and changes to its Board of Directors on March 28, 2023. Dr. Chris Savile has been appointed as President and CEO, succeeding Dr. Peter Seufer-Wasserthal, who will remain a director. Dr. Savile has been instrumental in developing Willow's biotechnological capabilities since its inception in 2019. Additionally, Dr. Trish Choudhary has been promoted to Sr. VP Research and Development. The Board will welcome Mr. Raffi Asadorian as an independent director post the AGM on May 12, 2023. These changes come as part of Willow's transition towards becoming a fully-integrated precision fermentation company.
On March 22, 2023, Willow Biosciences (CANSF) and Suanfarma announced the successful completion of pilot-scale development and manufacturing for Cannabigerol (CBG) at Suanfarma's CIPAN manufacturing site. The project aims to fulfill the production batches required for qualification and registration by the end of 2023.
Willow's CBG is positioned for health, wellness, and consumer care applications, demonstrating safety and efficacy as an antioxidant and anti-inflammatory agent. The partnership aims to offer an end-to-end synthetic biology solution and enhance their product portfolio for pharmaceuticals and natural ingredients.
Willow Biosciences Inc. has appointed Dr. Jim Lalonde as an independent member of its Board of Directors, effective February 21, 2023. Dr. Lalonde is recognized for his contributions to enzyme engineering and biocatalysis, which have significantly advanced chemical production and drug development. With a history of strengthening R&D teams and driving business growth, his expertise is expected to support Willow's focus on expanding its R&D capabilities and diversifying its portfolio. Dr. Lalonde aims to leverage Willow's precision fermentation technology to foster innovation in health, wellness, food, and personal care markets.
Willow Biosciences Inc. (OTCQB: CANSF) has announced a follow-on engagement with Sandhill One, LLC to optimize a proprietary enzyme for the production of ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient. This collaboration marks progress towards the company’s growth goals for 2023, aiming for increased revenue. The partnership with a major healthcare company focuses on a process that eliminates reliance on animal-sourced materials, promising cost-effective production. Willow anticipates several hundred thousand USD in research fees and future milestone payments as it moves towards commercialization of the enzyme by the end of the year.
Willow Biosciences Inc. (CANSF) has reviewed its key milestones achieved in 2022 and its business outlook for 2023. Major accomplishments include optimizing a new cannabigerol (CBG) process for commercial production, collaborations with Kalsec Inc., and the development of Astaxanthin, with a market potential exceeding $1 billion by 2027. For 2023, the company aims for substantial revenue growth, new partnerships, and efficient production. Willow has terminated a Joint Development Agreement for CBD to gain full control over its future in this market, emphasizing strategic optimization and a sustainable approach.
Willow Biosciences (CANSF) has announced strategic initiatives to enhance near-term revenue generation and minimize cash burn. Key actions include a shift towards revenue-generating pharmaceutical partnerships, consolidating R&D into a single lab in Mountain View, California, and outsourcing quality control testing. The company's workforce has been reduced to 31, with 77% in R&D, ensuring operational efficiency. As of September 30, 2022, Willow reported a strong cash position of $18.4 million with no debt, enabling a fully funded budget for 2023.
Willow Biosciences Inc. (TSX: WLLW, OTCQB: CANSF), a biotechnology leader, will host a webcast investor presentation on November 10, 2022, at 2:00 PM EST. The event will feature Willow's President and CEO, Dr. Peter Seufer-Wasserthal, and VP of Corporate Development, Troy Talkkari, discussing the company’s strategic areas. Investors can engage through a Q&A session. Pre-registration is required to access the live presentation. An archived version will be available on the company's website after the event.
Willow Biosciences Inc. (OTCQB: CANSF) announced its financial results for Q3 2022, reflecting strong liquidity with $18.7 million in working capital and $18.4 million in cash. The company appointed Dr. Peter Seufer-Wasserthal as President and CEO effective November 3, 2022, who had been interim CEO since July 2022. Willow is advancing its FutureGrown™ technology platform and has completed proof of concept for Astaxanthin. The company remains optimistic despite challenges in the cannabinoid market and is focusing on partnerships in the food and personal care sectors.